If You'd Invested in Moderna (MRNA) Stock 5 Years Ago, Here's How Much You'd Have Today (Hint: You'd Be Disappointed -- But Not If You Bought It 1 Year Ago.)
Key Points
Moderna has had great success with its mRNA technology used for vaccines.
Its promising trial results for a cancer vaccine have many investors excited.
- 10 stocks we like better than Moderna ›
Moderna (NASDAQ: MRNA) is famous for developing vaccines using mRNA technology (thus, its ticker symbol) -- including its highly popular COVID-19 vaccine a few years ago. Enthusiasm over that vaccine helped propel the stock some 434% in 2020 and another 143% in 2021. Wow, right?
But what has the stock done for shareholders lately? How has it done over the past five years? Not so great. It has averaged annual losses over that period -- enough to turn a single $10,000 investment in early September 2021 into just $3,792 in early September 2026. Ouch!
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
However, the story doesn't end there. What if you bought into the biotech stock with $10,000 just one year ago? Your stake would now be worth... $62,344. The stock has surged more than 500% over the past year!
The reason why is rather understandable: Moderna has been making some auspicious announcements. For starters, it has received regulatory approval for its updated COVID-19 vaccines. More intriguingly, it has also reported strong clinical trial results for its drug to treat melanoma, a form of skin cancer (the drug was developed in partnership with Merck). A potential vaccine against cancer is a big deal, obviously, and Moderna co-founder and board chair Noubar Afeyan has suggested that this vaccine could be a springboard for vaccines against kidney, bladder, and lung diseases, among other conditions.
Given all that, should you invest in Moderna now? Well, maybe. The company has been posting net losses instead of gains over the past few years, which isn't attractive. However, it also has far more cash than debt, which is promising. Another plus is Moderna's proprietary knowledge and technology, which isn't easy for a rival to duplicate. It has dozens of treatments in its pipeline, too.
Given Moderna's great promise, I think it's reasonable to buy a few shares now -- or wait and hope for a pullback. Research it further first, of course.
Should you buy stock in Moderna right now?
Before you buy stock in Moderna, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Moderna wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $421,997!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,413,876!*
Now, it’s worth noting Stock Advisor’s total average return is 978% — a market-crushing outperformance compared to 213% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 6, 2026.
Selena Maranjian has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Moderna. The Motley Fool has a disclosure policy.
Recommended Articles
